Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
This innovation — 3DPDMS — creates microfluidics in the industry-standard material at a speed and resolution to create true biological models that propel bioinnovation across the biotech industry.
Backed by two NIH grants, Phase, Inc. is currently working with the Virginia Tech - Wake Forest School of Biomedical Engineering and Sciences and Harvard Medical School to develop a microfluidic device that will allow researchers to develop new brain cancer treatments.
With a team of seasoned leaders in both 3D printing and biomedical engineering with advanced degrees from MIT and UC Berkeley, Phase is poised to lead the microfluidics industry in unlocking the next wave of medical breakthroughs.
